Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      SCHWAZZE ANNOUNCES FOURTH QUARTER 2022 & YEAR-END 2022 RESULTS

      WWW.SCHWAZZE.COM (CNW Group/Medicine Man Technologies, Inc.)

      News provided by

      Medicine Man Technologies, Inc.

      Mar 29, 2023, 17:00 ET

      Share this article

      Share this article


      OTCQX: SHWZ
      NEO: SHWZ

      Record 2022 Revenue Increases 47% to $159.4 Million Compared to $108.4 Million in 2021

      Company Continues to Grow Positive Cash Flow from Operations in Fourth Quarter and Year-End 2022

      Expansion into New Mexico Market as well as Colorado Acquisitions Add 23 Retail Dispensaries, One Manufacturing and Four Operating Cultivation Facilities

      Conference Call & Webcast Scheduled for Today – 5:00 pm ET

      DENVER, March 29, 2023 /PRNewswire/ - Medicine Man Technologies Inc. operating as Schwazze, (OTCQX: SHWZ) (NEO: SHWZ) ("Schwazze" or the "Company"), today announced financial results for the fourth quarter ("Q4 2022") and for the year ended December 31, 2022 ("2022"). 

       Full Year 2022 Financial Summary:

      • Revenues of $159.4 million, an increase of 47% compared to $108.4 million in 2021
      • Gross Profit of $85.0 million, an increase of 72% compared to $49.4 million in 2021
      • Net Loss of ($18.5) million compared to Net Income of $14.5 million for 2021, driven by an impairment charge of $8.0 million, interest expense of $30.1 million, and loss on disposition of assets of $4.7 million
      • Adjusted EBITDA of $52.0 million was 33% of revenue, compared to $32.2 million and 30% of revenue in 2021
      • Cash Flow from operations was $11.4 million compared to $8.4 million in 2021
      • Retail Sales of $141.3 million, an increase of 92% compared to $73.8 million in 2021
      • Two-year stacked identical retail sales ("Stacked IDs")(1) for Colorado and New Mexico were 7.9%

       Q4 2022 Financial Summary:

      • Revenues of $40.1 million, an increase of 51% compared to $26.5 million in Q4 2021
      • Gross Profit of $23.0 million, an increase of 89% compared to Q4 2021
      • Net Loss of ($27.3) compared to Net Income of $12.8 million for Q4 2021
      • Adjusted EBITDA of $13.3 million was 33% of revenue, compared to $7.5 million and 28% of revenue for Q4 2021
      • Cash Flow from operations for the quarter was $5.4 compared to $3.6 million for Q4 2021
      • Retail sales of $36.9 million, an increase of 87% over $19.7 million for Q4 2021
      • Stacked IDs(1) for Colorado and New Mexico were 5.3%

      Accomplishments for 2022 and Q1 2023

      In 2022, the Company completed seven acquisitions and opened six new stores not related to acquisitions, which increased the Company's retail presence from 18 dispensaries as of December 31, 2021 to 41 dispensaries as of December 31, 2022.  The Company now has five operating cultivation facilities and two manufacturing assets in Colorado and New Mexico. In Q1 2023, the Company subsequently announced the opening of two additional New Mexico retail locations and entry into a definitive agreement to acquire two retail dispensaries in Colorado from Smokey's Cannabis, which will bring the total dispensary count to 45.

      Recent Developments

      • Rolled out enhanced custom eCommerce platform in New Mexico for R.Greenleaf
      • Opened two new R.Greenleaf locations in New Mexico – Paseo and Carlsbad
      • Signed definitive agreement to acquire two retail dispensaries in Garden City and Fort Collins, Colorado, two attractive markets currently not served

      2022 Business Highlights and Significant Achievements

      • Entered the New Mexico market with the acquisition of ten retail locations, four indoor cultivation facilities and one manufacturing facility, establishing Schwazze as a regionally focused multi-state operator (MSO)
      • Opened six new stores in New Mexico under R.Greenleaf banner located in or near the University of New Mexico, Los Lunas, Clovis, Ruidoso, Sunland Park and Alamogordo
      • Acquired two retail dispensaries in Boulder, Colorado
      • Acquired an indoor cultivation facility in Denver, Colorado
      • Acquired two Emerald Field retail dispensaries in Glendale and Manitou Springs, Colorado
      • Acquired one retail dispensary and one indoor cultivation facility in Denver, Colorado
      • Acquired two retail dispensaries in Aurora and Denver, Colorado
      • Negotiated exclusive licensing, manufacturing and distribution agreement with Lowell Farms and launched premium pre-rolls in both Colorado and New Mexico
        • Launched new and enhanced custom eCommerce platform for Star Buds

      "In 2022, Schwazze continued to execute its strategy to "go deep" in our operating states and build customer loyalty and share," stated Justin Dye, CEO of Schwazze. "To date, we have opened, acquired, or announced pending acquisitions of 45 dispensaries with five operating cultivation and two manufacturing facilities across Colorado and New Mexico. We believe our retail brands are really connecting with customers. Schwazze is well-positioned to play offense in this challenging environment. As market forces become more favorable, we believe Schwazze will emerge with a much stronger position which will reward shareholders. For now, we will keep executing our strategy and playbook."

      "While we had seasonally lower quarter over quarter revenues, we recorded a solid fourth quarter and outpaced retail sales in the state of Colorado by 11%, despite a challenging environment and continued price compression," said Nirup Krishnamurthy, President of Schwazze. "Along with our New Mexico operations, revenue for the year increased by 47%, with retail sales growing 92% over the prior year with solid execution. In addition, we are focused on building a high-quality house of product brands that deliver good value to our customers. These results could not be achieved without the hard work and dedication of the entire Schwazze team."

      2022 Results of Operations

      Consolidated revenues for 2022, totaled $159.4 million, increasing $51.0 million or 47% over 2021 revenues of $108.4 million. This increase was influenced by several factors, including consummation of identified acquisitions, new store openings, entrance into the New Mexico market, and adult-use legalization taking effect in New Mexico in 2022.  Based on publicly available sales data, management estimates that overall cannabis sales in the New Mexico market increased approximately 75% as compared to 2021 sales because of increased adult-use recreational cannabis sales following its legalization in April 2022.

      Cost of goods and services for 2022, totaled $74.3 million compared to cost of goods and services of $59.1 million in 2021, representing an increase of $15.2 million, or approximately 26%. This increase is primarily due to the New Mexico acquisition and subsequent opening of six new stores in 2022.

      Gross profit increased to $85.0 million for the year compared to $49.4 million in 2021. Gross profit margin rose as a percentage of revenue from 46% to 53%, with improvements in our cost structure, buying power and retail playbook.

      Operating expenses for 2022, totaled $72.2 million, compared to operating expenses of $38.9 million during 2021, representing an increase of $33.2 million or approximately 85%. This increase was largely due to increased selling, general and administrative expenses related to acquisition growth, the New Mexico market entry, and includes certain one-time impairment charges for 2022.

      Other expense for 2022 was ($16.4) million, compared to other income of $8.5 million in 2021. This is largely driven by non-cash debt related interest obligations and a one-time disposition of assets.

      As a result of the factors discussed above, Schwazze generated a net loss of ($18.5) million for 2022 compared to net income of $14.5 million for 2021.

      Adjusted EBITDA for the year was $52.0 million representing 33% of revenue, compared to $32.2 million and 30% in 2021. This is derived from Operating Income and adjusting one-time expenses, merger and acquisition and capital raising costs, non-cash related compensation costs, and depreciation and amortization. See the financial table for Adjusted EBITDA below for details and a reconciliation to net income (loss). 

      For 2022, the Company generated positive operating cash flow of $11.4 million compared to $8.4 million for 2021 and had $38.9 million in cash and cash equivalents as of December 31, 2022. 

      Forrest Hoffmaster, CFO for Schwazze commented, "Despite the challenging economic backdrop, we've delivered an excellent year resulting in the continued generation of operating cash flows from our acquired businesses. This allows us to not only meet our borrowing obligations but reinvest in infrastructure improvements and in our strategy to go deep in both Colorado and New Mexico."

      (1)

      Stacked IDs are presented as a percentage that indicates the relative increase or decrease to revenue for certain retail stores from the previous two years. Stacked IDs are calculated by comparing revenue from sales for all dispensaries owned by the Company and open for operations for more than one year against the revenue from the sales for the same dispensaries for the previous two years. When the Company reports Stacked IDs for stores that it has not owned for more than one year, the comparison is made against validated sales data from prior owners of such stores provided to the Company upon acquisition and/or publicly available sales and revenue data. The Company did not own all the assets and entities in part of 2022, 2021 and 2020 and is using unaudited numbers for this comparison.



      Adjusted EBITDA represents income (loss) from operations, as reported, before tax, adjusted to exclude non-recurring items, other non-cash items, including stock-based compensation expense, depreciation, and amortization, and further adjusted to remove acquisition and capital raise related costs, and other one-time expenses, such as severance, retention, and employee relocation. The Company uses adjusted EBITDA as it believes it better explains the results of its core business.


      Webcast – March 29, 2023 – 5:00 pm ET
      Investors and stakeholders may participate in the conference call by dialing 416-764-8650 or by dialing North American toll free 1-888-664-6383 or listen to the webcast from the Company's website at https://ir.schwazze.com The webcast will be available on the Company's website and on replay until April 5, 2023, and may be accessed by dialing 1-416-764-8677 or North American toll free 1-888-390-0541 / 592815 #.

      Following their prepared remarks, Company management will answer investor questions. Investors may submit questions in advance or during the conference call itself through the weblink: https://app.webinar.net/x0q6rpnP84n  This weblink has been posted to the Company's website and will be archived on the website. All Company SEC filings can also be accessed on the Company website at https://ir.schwazze.com/sec-filings.

      About Schwazze
      Schwazze (OTCQX: SHWZ;  NEO: SHWZ) is building a premier vertically integrated regional cannabis company with assets in Colorado and New Mexico and will continue to take its operating system to other states where it can develop a differentiated regional leadership position. Schwazze is the parent company of a portfolio of leading cannabis businesses and brands spanning seed to sale. The Company is committed to unlocking the full potential of the cannabis plant to improve the human condition. Schwazze is anchored by a high-performance culture that combines customer-centric thinking and data science to test, measure, and drive decisions and outcomes. The Company's leadership team has deep expertise in retailing, wholesaling, and building consumer brands at Fortune 500 companies as well as in the cannabis sector. Schwazze is passionate about making a difference in our communities, promoting diversity and inclusion, and doing our part to incorporate climate-conscious best practices.

      Medicine Man Technologies, Inc. was Schwazze's former operating trade name. The corporate entity continues to be named Medicine Man Technologies, Inc. Schwazze derives its name from the pruning technique of a cannabis plant to enhance plant structure and promote healthy growth.

      Forward-Looking Statements
      This press release contains "forward-looking statements." Such statements may be preceded by the words "may," "will," "could," "would," "should," "expect," "intends," "plans," "strategy," "prospects," "anticipate," "believe," "approximately," "estimate," "predict," "project," "potential," "continue," "ongoing," or the negative of these terms or other words of similar meaning in connection with a discussion of future events or future operating or financial performance, although the absence of these words does not necessarily mean that a statement is not forward-looking. Forward-looking statements are not guarantees of future events or performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control and cannot be predicted or quantified. Consequently, actual events and results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) regulatory limitations on our products and services and the uncertainty in the application of federal, state, and local laws to our business, and any changes in such laws; (ii) our ability to manufacture our products and product candidates on a commercial scale on our own or in collaboration with third parties; (iii) our ability to identify, consummate, and integrate anticipated acquisitions; (iv) general industry and economic conditions; (v) our ability to access adequate capital upon terms and conditions that are acceptable to us; (vi) our ability to pay interest and principal on outstanding debt when due; (vii) volatility in credit and market conditions; (viii) the loss of one or more key executives or other key employees; and (ix) other risks and uncertainties related to the cannabis market and our business strategy. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise except as required by law.

      MEDICINE MAN TECHNOLOGIES, INC.
      CONDENSED CONSOLIDATED BALANCE SHEETS
      For the Years Ended December 31, 2022 and 2021
      Expressed in U.S. Dollars



      December 31, 


      December 31, 



      2022


      2021



      (Audited)


      (Audited)

      ASSETS







      Current assets







      Cash and cash equivalents


      $

      38,949,253


      $

      106,400,216

      Accounts receivable, net of allowance for doubtful accounts



      4,471,978



      3,866,828

      Inventory



      22,554,182



      11,121,997

      Note receivable - current, net



      11,944



      —

      Note receivable - related party



      —



      —

      Marketable securities, net of unrealized loss of $39,270 and gain of $216,771, respectively



      454,283



      493,553

      Prepaid expenses and other current assets



      5,293,393



      2,523,214

      Total current assets



      71,735,033



      124,405,808

      Non-current assets







      Fixed assets, net accumulated depreciation of $4,899,977 and $1,988,973, respectively



      27,089,026



      10,253,226

      Investments



      2,000,000



      —

      Goodwill



      94,643,581



      43,316,267

      Intangible assets, net accumulated amortization of $16,290,862 and $7,652,750, respectively



      107,726,718



      97,582,330

      Note receivable – noncurrent, net



      —



      143,333

      Accounts receivable – litigation



      —



      303,086

      Other noncurrent assets



      1,527,256



      514,962

      Operating lease right of use assets



      18,199,399



      8,511,780

      Total non-current assets



      251,185,980



      160,624,984

      Total assets


      $

      322,921,013


      $

      285,030,792








      LIABILITIES AND STOCKHOLDERS' EQUITY







      Current liabilities







      Accounts payable


      $

      7,886,893


      $

      2,548,885

      Accounts payable - related party



      22,380



      36,820

      Accrued expenses



      10,314,958



      5,592,222

      Derivative liabilities



      16,508,253



      34,923,013

      Notes payable - related party



      —



      134,498

      Lease liabilities - current



      3,139,289



      —

      Current portion of long term debt



      2,250,000



      —

      Income taxes payable



      7,297,815



      2,027,741

      Total current liabilities



      47,419,588



      45,263,179

      Long term debt, net of debt discount and issuance costs



      125,521,520



      97,482,468

      Lease liabilities



      17,314,464



      8,715,480

      Deferred income taxes, net



      502,070



      —

      Total long-term liabilities



      143,338,054



      106,197,948

      Total liabilities



      190,757,642



      151,461,127








      Commitments and contingencies (Note 17)



      —



      —








      Stockholders' equity







      Preferred stock, $0.001 par value. 10,000,000 shares authorized; 86,994 shares issued as of December 31, 2022 and December 31, 2021, 86,050 outstanding at December 31, 2022 and 82,594 outstanding at December 31, 2021.



      87



      87

      Common stock, $0.001 par value. 250,000,000 shares authorized; 56,069,212 shares issued and 54,741,506 shares outstanding at December 31, 2022 and 45,455,490 shares issued and 45,484,314 shares outstanding as of December 31, 2021.



      56,353



      45,485

      Additional paid-in capital



      180,381,640



      162,815,097

      Accumulated deficit



      (46,241,582)



      (27,773,968)

      Common stock held in treasury, at cost, 920,149 shares held as of December 31, 2022 and 517,044 shares held as of December 31, 2021



      (2,033,127)



      (1,517,036)

      Total stockholders' equity



      132,163,371



      133,569,665

      Total liabilities and stockholders' equity


      $

      322,921,013


      $

      285,030,792








      See accompanying notes to the consolidated financial statements

      MEDICINE MAN TECHNOLOGIES, INC.
      CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) AND INCOME
      For the Years Ended December 31, 2022 and 2021
      Expressed in U.S. Dollars



      Qtr Ended


      Qtr Ended


      Year Ended


      Year Ended



      December 31,


      December 31,


      December 31,


      December 31,



      2022


      2021


      2022


      2021



      (Un-audited)


      (Un-audited)


      (Audited)


      (Audited)

      Operating revenues









      Retail

      $

      36,868,429

      $

      19,677,130

      $

      141,254,893

      $

      73,761,010

      Wholesale


      3,158,670


      6,779,126


      17,819,938


      34,434,091

      Other


      120,188


      59,722


      304,388


      225,138

      Total revenue


      40,147,287


      26,515,978


      159,379,219


      108,420,239

      Total cost of goods and services


      17,176,229


      14,373,780


      74,349,421


      59,066,545

      Gross profit


      22,971,058


      12,142,198


      85,029,798


      49,353,694

      Operating expenses









      Selling, general and administrative expenses


      9,152,587


      3,035,837


      29,398,324


      16,616,306

      Professional services


      993,215


      880,238


      6,722,554


      5,346,934

      Loss on impairment


      8,011,405


      -


      8,011,405


      -

      Salaries


      6,435,095


      3,437,676


      25,369,968


      11,943,409

      Stock based compensation


      883,890


      1,172,291


      2,672,713


      5,037,879

      Total operating expenses


      25,476,192


      8,526,042


      72,174,964


      38,944,528

      Income from operations


      (2,505,134)


      3,616,156


      12,854,834


      10,409,166

      Other income (expense)









      Interest expense, net


      (6,827,557)


      (2,487,533)


      (30,139,645)


      (7,014,279)

      Gain on forfeiture of contingent liabilities


      -


      -


      -


      -

      Unrealized gain on derivative liabilities


      (9,690,200)


      14,093,391


      18,414,760


      15,061,142

      Other income


      3,736


      -


      24,136


      -

      Loss on business disposition


      (4,684,366)


      -


      (4,684,366)


      -

      Gain on sale of assets


      -


      -


      -


      242,494

      Unrealized (loss) gain on investments


      3,083


      6,086


      (39,270)


      216,771

      Total other (expense) income


      (21,195,304)


      11,611,944


      (16,424,385)


      8,506,128

      Pre-tax net (loss) income

      $

      (23,700,438)

      $

      15,228,100

      $

      (3,569,551)

      $

      18,915,294

      Provision for income taxes


      3,638,695


      2,398,259


      14,898,064


      4,396,164

      Net (loss) income

      $

      (27,339,133)

      $

      12,829,841

      $

      (18,467,615)

      $

      14,519,130

      Less: Accumulated preferred stock dividends for the period


      (2,508,677)


      (7,346,153)


      (7,802,809)


      (7,346,153)

      Net income attributable to common stockholders

      $

      (29,847,810)

      $

      5,483,688

      $

      (26,270,424)

      $

      7,172,977

      Earnings (loss) per share attributable to common shareholders









      Basic (loss) earnings per share

      $

      (0.53)

      $

      0.12

      $

      (0.49)

      $

      0.17

      Diluted (loss) earnings per share

      $

      (0.53)

      $

      (0.07)

      $

      (0.49)

      $

      (0.06)

      Weighted average number of shares outstanding - basic


      56,377,351


      44,145,709


      54,154,047


      43,339,092

      Weighted average number of shares outstanding - diluted


      56,377,351


      102,175,575


      54,154,047


      101,368,958

      Comprehensive (loss) income

      $

      (29,847,810)

      $

      5,483,688

      $

      (26,270,424)

      $

      7,172,977


                                                                                        See accompanying notes to the consolidated financial statements

      MEDICINE MAN TECHNOLOGIES, INC.
      CONSOLIDATED STATEMENTS OF CASH FLOWS
      For the Quarters & Years Ended December 31, 2022 and 2021
      Expressed in U.S. Dollars



      Qtr Ended


      Qtr Ended


      Year Ended


      Year Ended



      December 31,


      December 31,


      December 31,


      December 31,



      2022


      2021


      2022


      2021



      (Un-audited)


      (Un-audited)


      (Audited)


      (Audited)

      Cash flows from operating activities:









      Net income (loss) for the period

      $

      (27,339,133)

      $

      12,829,841

      $

      (18,467,615)

      $

      14,519,130

      Adjustments to reconcile net income to cash for operating activities









      Depreciation and amortization


      2,682,686


      797,037


      11,012,453


      8,576,865

      Non-cash interest expense


      981,369


      -


      4,118,391


      -

      Impairment of goodwill and intangibles


      8,011,080


      -


      8,011,080


      -

      Non-cash lease expense


      481,779


      -


      975,561


      -

      Deferred taxes


      (2,712,010)


      -


      (2,712,010)


      -

      Loss on disposition of business units


      4,684,369


      -


      4,684,369


      -

      Change in derivative liabilities


      9,690,200


      (14,093,391)


      (18,414,760)


      (15,061,142)

      Amortization of debt issuance costs


      421,513


      -


      1,686,049


      -

      Amortization of debt discount


      1,979,193


      -


      7,484,613


      -

      Loss (gain) on investment, net


      (3,083)


      (6,086)


      39,270


      (216,771)

      Loss on sale of asset


      -


      49,985


      -


      (242,494)

      Stock based compensation


      (662,307)


      1,172,291


      812,073


      5,037,879

      Changes in operating assets and liabilities (net of acquired amounts):









      Accounts receivable


      1,567,747


      2,424,575


      467,692


      244,929

      Inventory


      (2,039,758)


      (1,674,942)


      789,399


      (4,703,186)

      Prepaid expenses and other current assets


      (14,880)


      55,821


      (2,631,612)


      (1,909,014)

      Other assets


      (69,610)


      (60,900)


      (1,009,794)


      (457,083)

      Operating leases right of use assets and liabilities


      999,798


      23,010


      1,075,093


      137,139

      Accounts payable and other liabilities


      3,076,355


      1,062,106


      8,204,141


      493,719

      Deferred revenue


      -


      -


      -


      (50,000)

      Income taxes payable


      3,709,444


      998,259


      5,270,074


      2,027,741

      Net cash (used) provided by operating activities

      $

      5,444,752

      $

      3,577,606

      $

      11,394,467

      $

      8,397,712

      Cash flows from investing activities:









      Collection of notes receivable


      -


      -


      -


      181,911

      Cash consideration for acquisition of business, net of cash acquired


      (2,785,997)


      (3,750,929)


      (62,371,226)


      (75,678,000)

      Purchase of fixed assets


      (2,300,191)


      (1,768,427)


      (14,811,580)


      (5,638,085)

      Purchase of intangible assets


      -


      -


      -


      (29,580)

      Investment in private entity


      -


      -


      (2,000,000)


      -

      Net cash used in investing activities

      $

      (5,086,188)

      $

      (5,519,356)

      $

      (79,182,806)

      $

      (81,163,754)

      Cash flows from financing activities:









      Proceeds from issuance of debt


      -


      87,172,805


      -


      132,517,383

      Repayment of notes payable


      (134,498)


      -


      (134,498)


      (4,865,502)

      Proceeds from issuance of common stock, net of issuance costs


      -


      345


      471,874


      50,283,142

      Net cash provided by financing activities

      $

      (134,498)

      $

      87,173,150

      $

      337,376

      $

      177,935,023

      Net (decrease) increase in cash and cash equivalents


      224,066


      85,231,400


      (67,450,963)


      105,168,981

      Cash and cash equivalents at beginning of period


      38,725,187


      21,168,816


      106,400,216


      1,231,235

      Cash and cash equivalents at end of period

      $

      38,949,253

      $

      106,400,216

      $

      38,949,253

      $

      106,400,216

      Supplemental disclosure of cash flow information:









      Cash paid for interest

      $

      2,184,305

      $

      1,896,250

      $

      15,423,990

      $

      5,759,220

      Cash paid for income taxes

      $

      2,500,000

      $

      2,100,000

      $

      12,340,000

      $

      2,100,000


                                                                     See accompanying notes to the consolidated financial statements

      MEDICINE MAN TECHNOLOGIES, INC.
      Adjusted EBITDA Reconciliation
      Non-GAAP measurement
       (UNAUDITED)



      Qtr Ended


      Qtr Ended


      Year Ended


      Year Ended



      December 31,


      December 31,


      December 31,


      December 31,



      2022


      2021


      2022


      2021



      (Un-audited)


      (Un-audited)


      (Un-audited)


      (Un-audited)

      Net income (loss)

      $

      (27,339,133)

      $

      12,829,841

      $

      (18,467,615)

      $

      14,519,130

      Interest expense, net


      6,827,558


      2,487,533


      30,139,645


      7,014,279

      Provision for income taxes


      3,638,695


      2,398,259


      14,898,064


      4,396,164

      Other (income) expense, net of interest expense


      14,367,746


      (14,099,477)


      (13,715,260)


      (15,520,407)

      Depreciation and amortization


      3,701,128


      797,037


      12,524,677


      8,576,865

      Earnings before interest, taxes, depreciation and amortization (EBITDA) (non-GAAP measure)

      $

      1,195,994

      $

      4,413,193

      $

      25,379,511

      $

      18,986,031

      Non-cash stock compensation


      883,890


      1,172,291


      2,672,713


      5,037,879

      Deal related expenses


      1,914,820


      712,049


      6,822,111


      2,779,151

      Capital raise related expenses


      (257,271)


      256,321


      533,958


      1,512,565

      Inventory adjustment to fair market value for purchase accounting


      -


      -


      6,541,651


      2,164,686

      One-time cultivation asset impairment


      -


      -


      329,210


      -

      One-time goodwill impairment


      8,011,405


      -


      8,011,405


      -

      Severance


      263,374


      5,053


      334,910


      166,557

      Retention program expenses


      -


      1,188


      -


      90,250

      Employee relocation expenses


      (3,750)


      2,428


      15,360


      40,819

      Other non-recurring items


      1,276,064


      939,717


      1,369,386


      1,388,150

      Adjusted EBITDA (non-GAAP measure)

      $

      13,284,526

      $

      7,502,240

      $

      52,010,215

      $

      32,166,088

      Revenue

      $

      40,147,287

      $

      26,515,978

      $

      159,379,219

      $

      108,420,239

      Adjusted EBITDA as a Percentage of Revenue


      33.1 %


      28.3 %


      32.6 %


      29.7 %


                                                                                              See accompanying notes to the consolidated financial statements

      SOURCE Medicine Man Technologies, Inc.

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.